vimarsana.com

Latest Breaking News On - Astella xtandi - Page 1 : vimarsana.com

Prostate cancer ADC breaks FibroGen's clinical losing streak

Prostate cancer ADC breaks FibroGen's clinical losing streak
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Deyaa-adib
Astella-xtandi
William-blair
Roche-tecentriq
Exelixi-cabometyx
Astrazeneca
Pfizer
Chief-medical-officer-deyaa-adib
Francisco-based-fibrogen
Fortis-therapeutics

Pfizer/Astellas' Xtandi receives CHMP recommendation to treat recurrent prostate cancer

Pfizer/Astellas' Xtandi receives CHMP recommendation to treat recurrent prostate cancer
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Canada
Japan
United-states
American
America
Ahsan-arozullah
Astella-xtandi
European-medicines-agency
Committee-for-medicinal-products-human-use
American-urology-association-annual-meeting
Drug-administration
Pfizer

Health care professionals optimistic as tirzepatide approved for obesity treatment

Health care professionals optimistic as tirzepatide approved for obesity treatment
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

San-antonio
Texas
United-states
Paolo-tarantino
Astella-xtandi
Eli-lilly
Richard-smith
Chandler-park
Ttirzepatide-zepbound
Eli-lilly-zepbound
Astrazeneca-truqap
European-medicines-agency

Pfizer's Elrexfio granted EC approval for relapsed and refractory multiple myeloma

Pfizer's Elrexfio granted EC approval for relapsed and refractory multiple myeloma
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Astella-xtandi
Chris-boshoff
European-commission
Pfizer
Drug-administration

Xtandi Approved for Nonmetastatic Castration-Sensitive Prostate Cancer

The FDA has approved Xtandi (enzalutamide) to treat nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.

Astellas-pharma
Astella-xtandi
Pfizer
Drug-administration

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.